Our Pricing

Understanding Mounjaro Pens: Expert UK Guidance on Tirzepatide Injection Therapy

Mounjaro pens are pre-filled KwikPen injectors containing tirzepatide, a dual GIP/GLP-1 receptor agonist licensed in the UK for weight management in adults with obesity or overweight with weight-related comorbidities. Available from Cured Pharmacy at £124.99 per pen, these once-weekly injections have demonstrated significant weight reduction in clinical trials. All mounjaro pens require a clinical assessment by a UK-registered prescriber before dispensing.

How Mounjaro Pens Work for Weight Loss

Mounjaro pens deliver tirzepatide, a novel medication that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously [1]. This dual action enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, leading to reduced appetite and caloric intake. In the landmark SURMOUNT-1 trial, participants using tirzepatide achieved an average weight reduction of 20.9% at the 15 mg dose over 72 weeks [2].

Each mounjaro pen contains a single dose administered subcutaneously once weekly, typically in the abdomen, thigh, or upper arm. The medication's dual receptor mechanism distinguishes it from single GLP-1 agonists like semaglutide, potentially offering enhanced metabolic benefits. Patients generally start at 2.5 mg weekly, escalating every four weeks under prescriber guidance to optimise efficacy while minimising gastrointestinal side effects [1].

Mounjaro Pens Dosing Schedule and Titration

The standard titration protocol for mounjaro pens begins with 2.5 mg weekly for four weeks, serving as an initiation dose to improve gastrointestinal tolerability [3]. After this period, the dose increases to 5 mg weekly, with subsequent escalations to 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg at four-week intervals, subject to individual response and tolerability.

Our clinical team at Cured Pharmacy, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), provides personalised titration guidance during your online consultation. Each mounjaro pen is pre-filled with a specific dose strength, eliminating the need for manual dose adjustment. Patients should administer injections on the same day each week, with flexibility of up to three days earlier or later if necessary to maintain adherence [3].

Managing Dose Escalation Side Effects

Gastrointestinal symptoms such as nausea, diarrhoea, and constipation are most common during dose escalation phases with mounjaro pens [2]. These effects typically diminish within several weeks as the body adapts. Eating smaller, more frequent meals and avoiding high-fat foods can help manage these symptoms. If side effects become intolerable, your prescriber may recommend maintaining your current dose for an additional four weeks before attempting further escalation.

Purchasing Mounjaro Pens Through Cured Pharmacy

Cured Pharmacy offers mounjaro pens at £124.99 per pen, with an additional £20 off your first order using code Weightlossnew, bringing your initial cost to £124.99. All purchases require completion of a free online clinical assessment reviewed by our UK-registered prescribers, ensuring tirzepatide is safe and appropriate for your individual circumstances.

Our streamlined process takes under three minutes to complete, with prescriptions typically reviewed within 24 hours on weekdays. Once approved, mounjaro pens are dispensed from our GPhC-registered pharmacy (9012511) and dispatched via discreet next-day delivery across the UK. We guarantee 100% discreet packaging with no external branding, and all medicines are genuine UK-licensed products sourced through regulated pharmaceutical supply chains [4].

Transparent Pricing and No Hidden Fees

Unlike some providers, Cured Pharmacy displays exact mounjaro pens pricing before you begin your consultation, ensuring complete transparency. There are no subscription lock-ins or mandatory ongoing fees — you purchase only what you need, when you need it. Our pricing includes the medication, prescriber review, and standard delivery, with no additional consultation charges added at checkout.

Clinical Evidence Supporting Mounjaro Pens Efficacy

The SURMOUNT clinical trial programme provides robust evidence for tirzepatide's weight management efficacy delivered via mounjaro pens. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus weight-related comorbidities, demonstrating mean weight reductions of 15.0%, 19.5%, and 20.9% with 5 mg, 10 mg, and 15 mg doses respectively, compared to 3.1% with placebo over 72 weeks [2].

SURMOUNT-2 specifically examined tirzepatide in adults with type 2 diabetes, showing mean weight reductions of 12.8% with 15 mg versus 2.2% with placebo [5]. These trials established tirzepatide as one of the most effective pharmacological interventions for weight management currently available in the UK. The MHRA licensed Mounjaro for weight management in September 2023, and NICE is currently evaluating tirzepatide for potential NHS commissioning [4].

Proper Administration Technique for Mounjaro Pens

Mounjaro pens are designed as single-use KwikPen injectors with a simple three-step administration process. Before each injection, remove the pen from refrigerated storage 30 minutes prior to allow it to reach room temperature, which improves comfort during injection. Inspect the solution through the pen window — it should appear clear and colourless; do not use if cloudy or discoloured [3].

Select an injection site on your abdomen (at least 5 cm from your navel), front of thigh, or upper arm, rotating sites weekly to prevent lipodystrophy. Clean the area with an alcohol wipe, remove the pen cap, place the pen firmly against your skin at a 90-degree angle, and press the injection button until you hear a click. Hold the pen in place for 10 seconds to ensure complete dose delivery, then dispose of the used mounjaro pen in a sharps container [3].

Storage Requirements for Mounjaro Pens

Unused mounjaro pens must be stored in a refrigerator between 2°C and 8°C, protected from light in the original carton. Do not freeze; if a pen has been frozen, discard it. Once removed from the refrigerator for use, the pen may be kept at room temperature (up to 30°C) for up to 21 days if needed for travel or convenience. Always check the expiration date printed on each pen and never use expired medication [3].

Safety Considerations and Contraindications for Mounjaro Pens

Mounjaro pens are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) due to thyroid C-cell tumour risk observed in rodent studies [1]. They should not be used during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment and for two months after discontinuation.

Common side effects include nausea (occurring in up to 29% of patients), diarrhoea, vomiting, constipation, and abdominal pain, typically most pronounced during dose escalation [2]. Rare but serious adverse events include pancreatitis (discontinue immediately if suspected), gallbladder disease, acute kidney injury secondary to dehydration, and hypoglycaemia when used with insulin or sulfonylureas. Our prescribers at Cured Pharmacy carefully review your medical history during consultation to identify any contraindications before approving mounjaro pens [4].

Scientific References

1. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Eli Lilly and Company Limited.
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
3. Eli Lilly and Company. (2024). Mounjaro (tirzepatide) injection: Instructions for use. Lilly USA, LLC.
4. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Mounjaro 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg solution for injection in pre-filled pen. MHRA.
5. Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., ... & Davies, M. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 402(10402), 613-626.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.